Knock-down of SET in both CML cell lines as well as CML CD34+ primary patient samples restored PP2A activity indicating a causal role for SET in PP2A inhibition in these cells. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.